Oddity Tech Ltd. reported third quarter 2026 net revenue of $145 million, a 2% decline year-over-year, but better than expected. Adjusted EBITDA was $22 million, and the company raised its full-year net revenue and adjusted EBITDA guidance, signaling confidence in upcoming growth initiatives. Key growth drivers include strong performance from SpoiledChild and METHODIQ brands, with plans to expand product categories in 2027. The company maintains a strong liquidity position with $561 million in cash and investments, supporting its strategic goals.
Oddity Tech's third quarter 2026 results and raised full-year outlook provide context for market watchers. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 11, 2026 18:02 WIB: out of 150 priced US tech stocks, 105 rose and 42 fell. Notable movers include NBIS at USD 149.49 with a 1-day change of +11.56% and a typical hold time of 28 days, GPRO at USD 0.76 down 9.81% with a 46-day hold, and AXTI at USD 43.00 up 9.39% with a 19-day hold.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
